Overview

Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Patients will be randomized into two groups (1/1) during one year: - 40 mg adalimumab subcutaneously (sc) every other week - placebo The effect on x-rays and clinical parameters will be evaluated.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Ghent
Treatments:
Adalimumab